Literature DB >> 1676331

Neurotensin modulates autoreceptor mediated dopamine effects on midbrain dopamine cell activity.

W X Shi1, B S Bunney.   

Abstract

Interactions of neurotensin (NT) with midbrain dopamine (DA) neurons were studied in rats using microiontophoretic techniques. Local ejection of NT significantly increased (greater than 30%) the firing rate of a few DA cells (12/106). In most cases, however, iontophoretic NT produced no significant change in spontaneous activity. On the other hand, in these same cells, NT significantly attenuated the inhibition induced by either DA or quinpirole, a specific D2 agonist. Inhibition induced by DA was not attenuated by either glutamate or cholecystokinin, although both of them increase the firing rate of DA cells. The effect of NT appears to be selective as NT attenuated DA-induced inhibition without a measurable effect on either GABA-induced inhibition or glutamate-induced excitation of the same DA cells. Combined, these results suggest that NT's effect on DA cell activity is primarily a neuromodulatory one. As both NT and D2 receptors in midbrain DA cell areas are primarily located on DA cells, the above results also suggest that the observed interaction between NT and DA occurred at the DA cell level.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1676331     DOI: 10.1016/0006-8993(91)90043-u

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  18 in total

Review 1.  Dopamine D2 autoreceptor interactome: Targeting the receptor complex as a strategy for treatment of substance use disorder.

Authors:  Rong Chen; Mark J Ferris; Shiyu Wang
Journal:  Pharmacol Ther       Date:  2020-05-27       Impact factor: 12.310

2.  Opposing mechanisms of regulation of a G-protein-coupled inward rectifier K+ channel in rat brain neurons.

Authors:  B M Velimirovic; K Koyano; S Nakajima; Y Nakajima
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

Review 3.  Receptor-receptor interactions as an integrative mechanism in nerve cells.

Authors:  M Zoli; L F Agnati; P B Hedlund; X M Li; S Ferré; K Fuxe
Journal:  Mol Neurobiol       Date:  1993 Fall-Winter       Impact factor: 5.590

4.  Neurotensin attenuates the reduction in alcohol drinking produced by angiotensin II.

Authors:  L A Grupp; S Harding
Journal:  Psychopharmacology (Berl)       Date:  1996-05       Impact factor: 4.530

5.  Striatal dopamine receptor plasticity in neurotensin deficient mice.

Authors:  Lucy G Chastain; Hongyan Qu; Chase H Bourke; P Michael Iuvone; Paul R Dobner; Charles B Nemeroff; Becky Kinkead
Journal:  Behav Brain Res       Date:  2014-11-15       Impact factor: 3.332

6.  Activation of afferents to the ventral tegmental area in response to acute amphetamine: a double-labelling study.

Authors:  Joyce Colussi-Mas; Stefanie Geisler; Luc Zimmer; Daniel S Zahm; Anne Bérod
Journal:  Eur J Neurosci       Date:  2007-08       Impact factor: 3.386

7.  Treatment of PC12 cells by nerve growth factor, dexamethasone, and forskolin. Effects on cell morphology and expression of neurotensin and tyrosine hydroxylase.

Authors:  T Caillaud; W Y Opstal; V Scarceriaux; C Billardon; W Rostene
Journal:  Mol Neurobiol       Date:  1995 Apr-Jun       Impact factor: 5.590

8.  Neurotensin effect on Na+, K+-ATPase is CNS area- and membrane-dependent and involves high affinity NT1 receptor.

Authors:  María Graciela López Ordieres; Georgina Rodríguez de Lores Arnaiz
Journal:  Neurochem Res       Date:  2002-11       Impact factor: 3.996

9.  Modulation of locomotor activation by the rostromedial tegmental nucleus.

Authors:  Heather N Lavezzi; Kenneth P Parsley; Daniel S Zahm
Journal:  Neuropsychopharmacology       Date:  2014-08-28       Impact factor: 7.853

10.  Presynaptic action of neurotensin on dopamine release through inhibition of D(2) receptor function.

Authors:  Charbel S Fawaz; Philippe Martel; Damiana Leo; Louis-Eric Trudeau
Journal:  BMC Neurosci       Date:  2009-08-14       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.